Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11538859 | 0.77 | MAPT (0.45) | LMNAMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL31549227 | 0.77 | MAPK1 (0.45) | MAPK1LMNAMEN1KMT2APKM | |
| SCHEMBL6626640 | 0.75 | SMN1; SMN2 (0.45) | MAPK1MEN1KMT2APKMMAPT | |
| SCHEMBL2684237 | 0.75 | PKM (0.43) | LMNAMEN1KMT2APKMMAPT | |
| SCHEMBL28190418 | 0.75 | PKM (0.43) | LMNAMEN1KMT2APKMMAPT | |
| SCHEMBL11088223 | 0.75 | MAPK1 (0.44) | MAPK1LMNAMEN1KMT2APKM | |
| SCHEMBL2779430 | 0.74 | PKM (0.46) | LMNAMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL31031180 | 0.73 | MAPK1 (0.61) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3796044 | 0.73 | MAPK1 (0.61) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL28565287 | 0.73 | KMT2A (0.48) | LMNAMEN1KMT2APKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110407854-B | Novel tetracyclic compounds | 北京加科思新药研发有限公司 | 2020-09-15 | — | — | CN | disclosed |
| EP-0889036-B1 | HIV protease inhibitors | AGOURON PHARMA (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1301517-B1 | THIENOPYRROLIDINONES | HOFFMANN LA ROCHE (CH) | 2004-12-15 | — | — | EP | disclosed |
| EP-1301517-A1 | THIENOPYRROLIDINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-16 | — | — | EP | disclosed |
| US-6528653-B2 | E.g., 4,6-dihydro 4-(heterocyclic ring-methylene)thieno(2,3-b) pyrrolidin-5-one derivatives; tumor necrosis factor ) inhibitors; anticarcinogenic, -proliferative and -arthritic agents; Alzheimer's disease; cardiovascular disorders | HOFFMANN-LA ROCHE, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20020028841-A1 | Thienopyrrolidinones | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | US | disclosed |
| WO-2002002567-A1 | THIENOPYRROLIDINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028841-A1 | Thienopyrrolidinones | TNF, TYMP, TNFRSF1A | MAPK1 880/4885LMNA 3158/4885MEN1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.